Media.Player

Facile Expression and Purification of USP17 for use in Cancer Drug Discovery

Summary

Researchers from Purdue University have developed a methodology for the expression and purification of recombinant USP17, which allows for the utilization of a much wider array of techniques compared to cell based assays. Recombinant USP17 can be used for kinetic, structural, biochemical studies, and other studies of the enzyme and its response to drug candidates. The Purdue researchers' protocol and the resulting recombinant protein provide others with the tools to develop therapeutics against cancers in which USP17 regulation is a major component. This method will help advance the development of anticancer therapeutics that target USP17.

Technology Benefits

Recombinant protein now available Facilitates drug discovery

Technology Application

Drug Discovery Pharmaceutical industry Biomedical industry Biomedical and Pharmaceutical R&D Medical diagnosis

Detailed Technology Description

Andrew MesecarPurdue Biological SciencesAndrew MesecarPurdue Chemistry

Countries

United States

Application No.

None

*Abstract

*Background

USP17, a ubiquitin specific enzyme, is responsible for the progression of the cell cycle to promote cellular proliferation. In many cancers, including breast and prostate, USP17 levels are upregulated, promoting unregulated proliferation and cancer. Over the last 10 years, cell-based studies have identified USP17 as a potential target for cancer therapy; however, there has been no advancement in the production of recombinant USP17. Availability of large amounts of purified, recombinant USP17 is critical for developing an anticancer therapeutic against this target.

*IP Issue Date

None

*IP Type

Provisional

*Stage of Development

Prototype testing in economic run

*Web Links

Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipAndrew MesecarPurdue Biological SciencesAndrew MesecarPurdue Chemistry

Country/Region

USA